Trials / Completed
CompletedNCT01999673
Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer
SUNRISE: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Previously Treated Stage IIIb/IV Non-Squamous Non Small-Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 582 (estimated)
- Sponsor
- Peregrine Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to the standard chemotherapy drug docetaxel, will improve the results of the treatment for non-small-cell lung cancer.
Conditions
- Non-Small-Cell Lung Cancer Stage IIIB
- Non-Small-Cell Lung Cancer Stage IV
- Non-Small-Cell Lung Cancer Metastatic
- Carcinoma, Non-Small-Cell Lung
- Non-Small Cell Lung Cancer
- Non-Small-Cell Lung Carcinoma
- Nonsmall Cell Lung Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | bavituximab | |
| DRUG | Docetaxel | |
| OTHER | Placebo (for bavituximab) |
Timeline
- Start date
- 2013-12-01
- Primary completion
- 2017-03-01
- Completion
- 2017-03-01
- First posted
- 2013-12-03
- Last updated
- 2017-04-21
Locations
161 sites across 14 countries: United States, Australia, Belgium, France, Germany, Greece, Hungary, Italy, Romania, Russia, South Korea, Spain, Taiwan, Ukraine
Source: ClinicalTrials.gov record NCT01999673. Inclusion in this directory is not an endorsement.